

RESEARCH

Open Access



Association of blood neutrophil-lymphocyte ratio with short-term prognosis and severity of tuberculosis meningitis patients without HIV infection

Zhihan Gu¹, Bofu Liu¹, Xiaomin Yu², Tao Cheng¹, Tianyong Han¹, Le Tong¹ and Yu Cao^{1*}

Abstract

Background Predicting the short-term prognosis and severity of tuberculosis meningitis (TBM) patients without HIV infection can be challenging, and there have been no prior studies examining the neutrophil lymphocyte ratio (NLR) as a potential predictor of short-term prognosis or its relationship to TBM severity. We hypothesized that NLR might serve as an independent indicator of short-term prognostic significance and that there might be a correlation between NLR and severity. The aim of this study was to investigate the role of NLR as a predictor of short-term prognosis and its relationship to severity of tuberculosis meningitis patients without HIV infection.

Methods We retrospectively collected data from patients diagnosed with TBM in the West China Hospital, Sichuan University, from the period between January 1st, 2018 and August 1st, 2019. Multivariable analysis was executed by the logistic regression model to verify the independence of the 28-day mortality, the discriminative power for predicting short-term prognosis was evaluated using a Receiver Operating Characteristic (ROC) curve, survival outcomes were analyzed using the Kaplan-Meier method and Pearson's correlation analysis was performed to discuss correlation between NLR and the severity of TBM.

Results We collected data from 231 TBM patients without HIV infection. 68 (29.4%) patients are classified as stage (I) 138(59.8%) patients are stage (II) 25(10.8%) patients are stage (III) 16(6.9%) patients died during the follow-up period of 28 days. By multiple logistic regression analyses, the NLR (OR = 1.065, 95% CI = 1.001–1.133, P = 0.045), peripheral neurological deficit (OR 7.335, 95% CI 1.964–27.385, P = 0.003) and hydrocephalus (OR 11.338, 95% CI 2.397–53.633, P = 0.002) are independent risk factors of 28-day mortality. The area under the ROC curve (AUC) for predicting short prognosis using NLR is 0.683 (95% CI 0.540–0.826, P = 0.015), the optimal cutoff value is 9.99(sensitivity: 56.3%, specificity: 80.9%). The Kaplan-Meier analysis demonstrated that patients with higher NLR(>9.99) had significantly worse survival outcomes(P<0.01).Pearson's correlation analysis presents a significant positive correlation between the severity of TBM and NLR (r = 0.234, P<0.01).

*Correspondence:

Yu Cao
yuyuer@126.com

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Conclusions NLR, peripheral neurological deficit, and hydrocephalus are independent risk factors of 28-day mortality, NLR can predict the short-term prognosis of TBM patients without HIV infection. NLR is also found to be significantly and positively correlated with the severity of TBM.

Keywords Tuberculosis meningitis, Neutrophil-lymphocyte ratio (NLR), Prognosis, Severity

Introduction

Tuberculosis (TB) is the major cause of death by an infectious disease worldwide [1]. However, tuberculosis meningitis (TBM) is considered the most devastating manifestation of *Mycobacterium tuberculosis* infection [2]. TBM is an inflammatory condition caused by the invasion of *Mycobacterium tuberculosis* into the human central nervous system, including the spinal cord, meninges, or brain parenchyma, which can lead to a series of secondary pathophysiological changes in the brain of affected patients [3]. The clinical course of TBM without HIV infection is nonspecific and quite variable. Additionally, various complex factors can impact the prognosis of patients with this disease. However, early identification of high-risk patients, along with intensive treatment, may help improve their prognosis [4]. So, assessment of the sufficient risk factor in patients with TBM is crucial in making clinical decisions.

Even given anti-tuberculosis treatment, The mortality rate of TBM patients as high as 10–50% [5]. Some studies indicated that factors such as disturbance of consciousness and hydrocephalus might be correlated with poor prognosis for patients with TBM [2, 5, 6]. However, the marker of inflammation in the blood has not been reported about the short-term prognosis of TBM patients.

Neutrophil-lymphocyte ratio (NLR) is defined as the number of neutrophils in whole blood divided by the number of lymphocytes in whole blood [7], it is a biomarker derived from leukocytes as a marker of inflammation. The NLR describes a reliable parameter to describe the immune response to various stimuli/stressors [8] and it has been found to be a useful biomarker for predicting prognosis or severity in various clinical settings including sepsis, military tuberculosis and bacterial meningitis [8–10], but the association of NLR with clinical prognosis and severity in TBM patients without HIV infection has not been reported. This study is expected to determine whether NLR is an independent predictor of short-term prognosis in TBM patients without HIV infection and the relationship between NLR and the severity of TBM.

Methods

Patients and diagnosis of TBM

We retrospectively collected the data of all patients (≥ 18 year-old) who were admitted to the West China Hospital, Sichuan University and diagnosed with TBM, from the period between January 1st, 2018 and August

1st, 2019. Patients were eligible for inclusion according to the standardized case definition of TBM proposed by Marais including the clinical criteria, CSF criteria, cerebral imaging criteria, evidence of tuberculosis elsewhere and exclusion of alternative diagnoses: An alternative diagnosis must be confirmed microbiologically, serologically, or histopathologically [11]. Patients with data was insufficient, HIV infection and pregnant were excluded from the study.

Collection of clinical data

The data information of patients was obtained by the patients' electronic medical record management system and telephone. At the time of admission, the following data were collected, including demographic information (sex, age, disease duration), clinical criteria (fever ($>37.5^{\circ}\text{C}$) >5 days, night sweats, weight loss, cough, headache, vomiting, peripheral neurological deficit, cognitive impairment, change in consciousness, cranial nerve palsy, and seizures), laboratory data (red blood cell, white blood cell, platelet, neutrophil, lymphocyte, the neutrophil-lymphocyte ratio (NLR), Serum sodium, Serum potassium, plasma glucose, albumin, CSF leukocyte count, CSF protein, CSF chlorine, CSF glucose, ratio of CSF to blood glucose), and cerebral imaging criteria (hydrocephalus, basal meningeal enhancement, tuberculoma, and infarct). We collected the severity of TBM at the time of admission which was assessed using the British Medical Research Council (BMRC) TBM stages modified as grade I (GCS 15; no focal neurological signs), grade II (GCS 11–14, or 15 with focal neurological signs), and grade III (GCS ≤ 10) disease [11], and also collected the outcome (survivors and non-survivors) after 28 days via telephone call.

Management

Patients received four TBM treatments, isoniazid (10–20 mg/kg/day; maximum 1200 mg/day), rifampicin (10–20 mg/kg/day; maximum 600 mg/day), pyrazinamide (20–30 mg/kg/day; maximum 1500 mg/day), and ethambutol: (15–20 mg/kg/day; maximum 750 mg/day), they also received dexamethasone (0.4 mg/kg/day; maximum 16 mg/day) at the same time of diagnosis, administered for 4 weeks.

Statistical analysis

A chi-squared or Fisher's exact test was implemented to compare the categorical variables. An

independent-sample test was utilized to compare the continuous variables. Multivariable analysis was executed by the stepwise logistic regression model (forward) to verify the independence of the 28-day mortality, and the Lemeshow-Hosmer χ^2 statistics was used to evaluate the Goodness-of-fit of the Multivariable logistic regression model. The discriminative power for predicting short-term prognosis was evaluated using a Receiver Operating Characteristic (ROC) curve, survival outcomes were analyzed using the Kaplan-Meier method. Pearson's correlation analysis was performed to discuss correlation about and the severity of TBM. All statistical analyses were implemented with the use of SPSS software version 22.0 (USA, IBM analytics). A P value equal or less than 0.05 was statistically significant in all analyses.

Results

There were 245 patients with TBM who were treated at the West China Hospital, Sichuan University. 14 patients were excluded from the study because of insufficient data or HIV infection, finally, a total of 231 patients were analyzed in this study. During the study period, 16 patients (6.9%) died while the remaining 215 (93.1%) survived.

In the study, there are 129 (55.8%) men, the average age of all patients is 36 ± 16 years. The patients are classified

into three stages according to the severity: 68 (29.4%) are in stage I, 138 (59.8%) are in stage II, and 25 (10.8%) are in stage III.

Tables 1 and 2 describes the patients' characteristics between the survivors and deaths. The most common symptoms of TBM are fever, headache, and vomiting, with an incidence rate of over 50%. Survivors exhibit a lower incidence of peripheral neurological deficit ($P < 0.001$), change in consciousness ($P = 0.002$), and hydrocephalus ($P < 0.001$) compared to those who died. NLR are higher in the deaths compared with survivors ($P = 0.003$), and albumin are lower in the deaths ($P = 0.045$). There is no significant statistical difference in the other factors.

In this study, seven single factors including peripheral neurological deficit, change in consciousness, hydrocephalus, NLR, albumin, age, and seizures were included in a multiple logistic regression analysis, and it was found that the NLR is an independent risk factor for 28-day mortality (OR = 1.065, 95% CI = 1.001–1.133, $P = 0.045$). In addition, peripheral neurological deficit (OR 7.335, 95% CI 1.964–27.385, $P = 0.003$) and hydrocephalus (OR 11.338, 95% CI 2.397–53.633, $P = 0.002$) were significantly more likely in deceased patients than in survivors (refer to Table 3). Neither the rate of change in consciousness, albumin, age and seizures are independent risk factors for 28-day mortality of patients with TBM. The Hosmer-Lemeshow χ^2 statistics of the multivariate logistic regression models is 2.260 ($P = 0.972$).

The area under the ROC curve (AUC) for predicting short-term prognosis in patients with TBM using NLR is 0.683 (95% CI 0.540–0.826, $P = 0.015$), with an optimal cutoff value of 9.99. When using this cutoff, NLR has a sensitivity of 56.3% and specificity of 80.9% for predicting short-term prognosis (refer to Fig. 1).

Patients were classified into the high NLR group and the low NLR group using a cutoff value of 9.99. Compared to the low NLR group, patients in the high NLR group exhibited higher incidence rates of changes in consciousness, hydrocephalus, and basal meningeal enhancement. Furthermore, they had significantly elevated levels of white blood cells and plasma glucose, and significantly reduced levels of albumin, serum sodium, CSF glucose, CSF chlorine, and the ratio of CSF to blood glucose (refer to Tables 4 and 5). Moreover, patients in the high NLR group had a higher 28-day mortality rate (refer to Table 5). The Kaplan-Meier analysis demonstrated that patients with high NLR had significantly worse survival outcomes ($P < 0.05$) (refer to Fig. 2).

The Study also explored the relationship between the severity of TBM and the NLR. The NLR values for patients with stage I TBM are 6.00 ± 5.03 , while those for patients with stage II TBM are 7.56 ± 6.33 , and for patients with stage III TBM, the NLR values are

Table 1 The TBM¹ patient's general characteristics without HIV infection

Variable	Overall cases (n = 231)	Survivors (n = 215)	Non-survivors (n = 16)	P
Sex				
Male, n, %	129(55.8%)	119(55.3%)	10(62.5%)	0.578
Age, years, mean \pm sd	36 \pm 16	36 \pm 16	34 \pm 16	0.618
Disease duration ^a , day, median, Interquartile range 25%, 75%	28(14, 60)	28(14, 60)	25(12, 32)	0.559
Fever (> 37.5°C) > 5days, n, (%)	188(81.4%)	177(82.3%)	11(68.8%)	0.178
Night sweats, n, (%)	53(22.9%)	51(23.7%)	2(12.5%)	0.303
Weight loss n, (%)	80(34.0%)	76(34.9%)	4(25%)	0.587
Cough, n, (%)	50(21.6%)	45(20.9%)	5(31.3%)	0.334
Headache, n, (%)	210(90.9%)	197(91.6%)	13(81.3%)	0.164
Vomiting, n, (%)	150(63.8%)	141(64.4%)	9(56.3%)	0.513
Peripheral neurological deficit ^b , n, (%)	69(29.9%)	57(26.5%)	12(75.0%)	0.000
Cognitive impairment, n, (%)	42(18.2%)	37(17.2%)	5(31.3%)	0.160
Change in consciousness, n, (%)	103(44.6%)	90(41.9%)	13(81.3%)	0.002
Cranial nerve palsy, n, (%)	57(24.7%)	51(23.7%)	6(37.5%)	0.217
Seizures, n, (%)	39(16.9%)	34(15.8%)	5(31.3%)	0.112

Note: ¹TBM: Tuberculosis meningitis; ^aDisease duration: Length of time from onset to hospital treatment; ^bPeripheral neurological deficit: the patient has limb numbness, limb movement disorder, fine motor loss and other manifestations

Table 2 The TBM¹ patient's laboratory and imaging characteristics without HIV infection

Variable	Overall cases (n = 231)	Survivors (n = 215)	Non-survivors (n = 16)	P
Laboratory data				
Red blood cell, 10 ¹² /L, mean ± sd	4.44 ± 0.59	4.44 ± 0.59	4.51 ± 0.65	0.651
Platelet 10 ⁹ /L, mean ± sd	240 ± 100	241 ± 102	225 ± 67	0.546
White blood cell, 10 ⁹ /L, mean ± sd	7.95 ± 3.46	7.84 ± 3.25	9.54 ± 5.53	0.244
Neutrophil, 10 ⁹ /L, mean ± sd	6.19 ± 3.37	6.06 ± 3.19	7.86 ± 5.08	0.181
Lymphocyte, 10 ⁹ /L, mean ± sd	1.13 ± 0.71	1.15 ± 0.72	0.87 ± 0.64	0.132
The neutrophil- lymphocyte ratio(NLR),%	7.58 ± 6.66	7.21 ± 6.31	12.51 ± 9.22	0.003
Serum sodium, mmol/L, mean ± sd	132.1 ± 7.7	131.9 ± 7.8	135.0 ± 5.5	0.122
Serum potassium, mmol/L, mean ± sd	3.70 ± 0.47	3.71 ± 0.47	3.56 ± 0.48	0.212
Plasma glucose, mmol/L, mean ± sd	6.09 ± 1.47	6.07 ± 1.48	6.41 ± 1.22	0.374
Albumin, g/L, mean ± sd	38.4 ± 5.0	38.5 ± 4.9	35.9 ± 6.5	0.045
CSF ^a leukocyte count, cell/ul, median, Interquartile range 25%,75%)	120(60,270)	120(60, 270)	125(43, 350)	0.932
CSF ^a protein, g/L, median, Interquartile range 25%,75%)	1.67(1.09,2.56)	1.56(1.08, 2.54)	2.29(1.17, 4.90)	0.104
CSF ^a chlorine, mmol/L, mean ± sd	113.93 ± 8.37	114.10 ± 8.27	111.83 ± 9.74	0.299
CSF ^a glucose, mmol/L, mean ± sd	2.05 ± 1.02	2.05 ± 0.99	2.06 ± 1.40	0.952
Ratio of CSF ^a to blood glucose, mean ± sd	0.353 ± 0.186	0.354 ± 0.182	0.336 ± 0.234	0.697
Cerebral imaging criteria				
Hydrocephalus, n, (%)	73(31.6%)	59(27.4%)	14(87.5%)	0.000
Infarct, n, (%)	94(40.7%)	85(39.5%)	9(56.3%)	0.189
Basal meningeal enhancement, n, (%)	78(33.8%)	71(33.0%)	7(43.8%)	0.381
Tuberculoma, n, (%)	7(3.0%)	6(2.8%)	1(6.3%)	0.399

Note: ¹TBM: Tuberculosis meningitis; ^aCSF: Cerebrospinal fluid

Table 3 The multivariate analysis result ¹ of 28-day mortality in TBM² patients without HIV infection

Variable	OR ^b	95%CI ^c	P
The neutrophil lymphocyte ratio(NLR)	1.065	1.001, 1.133	0.045
Peripheral neurological deficit ^a	7.335	1.964, 27.385	0.003
Hydrocephalus	11.338	2.397, 53.633	0.002

Note: ¹The multivariate analysis result was adjusted to age, clinical presentations, and albumin levels; ² TBM: Tuberculosis meningitis; ^aPeripheral neurological deficit: the patient has limb numbness, limb movement disorder, fine motor loss and other manifestations; ^bOR: odds ratio; ^cCI: confidence interval

12.00 ± 9.92. Pearson's correlation analysis presents a significant positive correlation between the severity of TBM and NLR ($r=0.234$, $P<0.01$).

Discussion

In this study, NLR was found to be an independent predictor of short-term prognosis in TBM patients without HIV infection. Patients with NLR greater than 9.99 had worse survival outcomes. In a number of studies, it has been reported that high NLR is associated with high mortality in cancers [12–14] or cardiovascular diseases [9, 15, 16]. NLR is a readily obtainable inflammatory marker that indicates the degree of neutrophil elevation or lymphocyte depletion. At present, the cause for the correlation between the increase in NLR and poor outcome has not yet been explained clearly. High neutrophil counts or lymphopenia may be associated with poor prognosis in several previous studies on TB [17–19], but NLR has not been represented in TBM patients. Chedid, C hypothesized that high neutrophil counts and low




Fig. 1 The ROC curves for predicting short-term prognosis in TBM patients without HIV infection by using NLR

lymphocyte proportions had highly inflammatory clinical patterns by the context of mycobacterial infection [17], which are markers of persisting inflammation or failure to clear the bacteria [20]. High neutrophil counts may reflect the presence of delayed apoptosis in inflammatory condition, and inhibit the anti-inflammatory ability of neutrophil cells [21]. In chronic TB infection, sustained

Table 4 Comparison of general characteristics between patients with high and low NLR¹

Variable	Overall cases (n = 231)	Survivors (n = 215)	Non-survivors (n = 16)	P
Sex				0.729
Male, n, %	129/55.8%	100(55.2%)	29(58.0%)	
Age, years, mean ± sd	36 ± 16	36 ± 16	37 ± 18	0.561
Fever(> 37.5°C) > 5days, n,(%)	188(81.4%)	148(81.8%)	40(80%)	0.776
Night sweats, n, (%)	53(22.9%)	43(23.8%)	10(20.0%)	0.576
Weight loss n, (%)	80(34.0%)	64(35.3%)	16(32%)	0.693
Cough, n, (%)	50(21.6%)	37(20.4%)	13(26.0%)	0.398
Headache, n, (%)	210(90.9%)	167(92.3%)	43(86%)	0.173
Vomiting, n, (%)	150(63.8%)	141(64.4%)	9(56.3%)	0.513
Peripheral neurological deficit ^a , n, (%)	69(29.9%)	52(28.7%)	17(34%)	0.471
Cognitive impairment, n, (%)	42(18.2%)	32(17.7%)	10(20.0%)	0.706
Change in consciousness, n, (%)	103(44.6%)	70(38.7%)	33(66.0%)	0.001
Cranial nerve palsy, n, (%)	57(24.7%)	44(24.3%)	13(26.0%)	0.806
Seizures, n, (%)	39(16.9%)	30(16.6%)	9(18.0%)	0.812

Note: ¹ NLR: neutrophil-lymphocyte ratio; ^aPeripheral neurological deficit: the patient has limb numbness, limb movement disorder, fine motor loss and other manifestations




Fig. 2 The results of the Kaplan-Meier analysis that TBM patients with high NLR and low NLR

inflammation which was an impairment maker of the TB-specific immune response and a marker of active disease has been reported [22]. High NLR may represent relative lymphopenia, low lymphocyte counts are associated with a negative response to treatment [17, 23] in relation to cell-mediated immunity which is important in the immune response to *M. tuberculosis* [9]. So, the similar

Table 5 Comparison of laboratory characteristics, imaging characteristics and prognosis between patients with high NLR¹ and low NLR¹

Variable	Overall cases (n = 231)	Low (n = 181)	High (n = 50)	P
Laboratory data				
Red blood cell, 10 ¹² /L, mean ± sd	4.44 ± 0.59	4.47 ± 0.58	4.36 ± 0.63	0.270
Platelet 10 ⁹ /L, mean ± sd	240 ± 100	237 ± 95	249 ± 116	0.472
White blood cell, 10 ⁹ /L, mean ± sd	7.95 ± 3.46	7.23 ± 2.90	10.56 ± 4.08	0.000
Serum sodium, mmol/L, mean ± sd	132.1 ± 7.7	132.9 ± 7.6	129.4 ± 7.4	0.004
Serum potassium, mmol/L, mean ± sd	3.70 ± 0.47	3.72 ± 0.46	3.63 ± 0.49	0.250
Plasma glucose, mmol/L, mean ± sd	6.09 ± 1.47	5.91 ± 1.42	6.76 ± 1.47	0.000
Albumin, g/L, mean ± sd	38.4 ± 5.0	38.9 ± 4.5	36.4 ± 6.2	0.002
CSF ^a leukocyte count, cell/ul, median, Interquartile range 25%, 75%)	120(60, 270)	110(60, 275)	130(58, 253)	0.933
CSF ^a protein, g/L, median, Interquartile range 25%, 75%)	1.67(1.09, 2.56)	1.67(1.04, 2.54)	1.62(1.17, 2.79)	0.456
CSF ^a chlorine, mmol/L, mean ± sd	113.93 ± 8.37	115.12 ± 8.04	109.64 ± 8.20	0.000
CSF ^a glucose, mmol/L, mean ± sd	2.05 ± 1.02	2.17 ± 1.04	1.58 ± 0.81	0.000
Ratio of CSF ^a to blood glucose, mean ± sd	0.353 ± 0.186	0.383 ± 0.185	0.247 ± 0.147	0.000
Cerebral imaging criteria				
Hydrocephalus, n, (%)	73(31.6%)	46(25.4%)	27(54.0%)	0.000
Infarct, n, (%)	94(40.7%)	71(39.2%)	23(46.0%)	0.388
Basal meningeal enhancement, n, (%)	78(33.8%)	55(30.4%)	23(46.0%)	0.039
Tuberculoma, n, (%)	7(3.0%)	5(2.8%)	2(4.0%)	0.647
28-day mortality n, (%)	16(6.9%)	7(3.9%)	9(18.0%)	0.000

Note: ¹ NLR: neutrophil-lymphocyte ratio; ^aCSF: Cerebrospinal fluid

pathway may have affected the progression and prognosis of TBM.

The study also investigates the association of high NLR with the severity of TBM. The higher NLR represents the higher the clinical stage, as some studies have reported a link between high NLR and higher cancer stage [13, 19, 24] and the severity of pulmonary TB [25]. When the NLR of TBM patients is greater than 9.99, they are more likely to experience altered consciousness and develop complications such as hydrocephalus, hyponatremia, and hypoproteinemia. These factors indicate that the patient may have a higher severity.

In this study, peripheral neurological deficit is a predictor of poor prognosis in TBM patients. A series of studies had reported similar conclusion [26–28]. About 15–50% of patients with TBM have exist peripheral neurological deficit when they first present symptom [27–30], this study reported 30% (69/231) of patients with TBM. This condition may be associated with high rates of morbidity and mortality. Some studies also reported cranial nerve palsy is a risk factors association with bad prognosis [30, 31],but this study did not support it. This study focused the 28-day mortality however those studies had a long-term follow-up result.

Hydrocephalus is a quite common complication of TBM, as reported, up to 60% of patients with TBM be found to by cranial imaging such as MRI/CT [32]. Patients with hydrocephalus may be associated with the pathogenesis of meningeal exudate, as well as either over-production of cerebrospinal fluid (CSF) or malfunctioning absorption of CSF in the subarachnoid space [33, 34], and it is considered to be an important risk factor for poor prognosis.

Limitations

This study suggests that NLR is a useful predictor of short-term prognosis for TBM patients without HIV infection, but it has several limitations. Firstly, the sample size was small, with only 16 deaths occurring within 28 days, which could potentially affect the stability of the logistic model. Additionally, the diagnosis primarily relied on clinical criteria, CSF criteria, and cerebral imaging criteria, which may introduce bias into the data. This study did not exclude patients who temporarily discontinued anti-tuberculosis treatment due to medication side effects. Furthermore, potential drug-resistant patients were not identified due to the lack of drug resistance testing. These factors have the potential to impact the study's results. Further studies with larger sample sizes are necessary to validate the effect of NLR values on the short-term prognosis of TBM patients without HIV infection.

Conclusions

NLR, peripheral neurological deficit, and hydrocephalus are independent risk factors of 28-day mortality, NLR can predict the short-term prognosis in TBM patients without HIV infection. NLR is also found to be significantly and positively correlated with the severity of TBM. Therefore, TBM patients without HIV infection who have high NLR values should be closely monitored in clinical practice.

Abbreviations

BMRC	British Medical Research Council
CI	Confidence interval
CNS	Central nervous system
CSF	Cerebrospinal fluid
GCS	Glasgow Coma Scale
HIV	Human immunodeficiency virus
NLR	Neutrophil-lymphocyte ratio
OR	Odds ratio
ROC	Receiver Operating Characteristic
TB	Tuberculosis
TBM	Tuberculosis meningitis

Acknowledgements

We acknowledge all the participants for their cooperation.

Authors' contributions

ZG conceived the study, drafted the manuscript, analyzed the data and critically revised the manuscript for important intellectual content; BL analyzed of the data; XY, TC, TH and LT were involved in the diagnosis and confirmation of tuberculous meningitis patient. Corresponding author was responsible for study concept design; analysis, interpretation and integrity of the data, preparation of the manuscript and reviewed the manuscript for intellectual content. All authors read and approved the final manuscript.

Funding

No specific funding was available for this study.

Data Availability

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

The study was approved by the Human Ethics Committee of West China Hospital of Sichuan University (ethics No.: 2018–598) and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects and/or their legal guardian(s). All methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Emergency Medicine, Laboratory of Emergency Medicine, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China

²Disaster Medical Center, Sichuan University, Chengdu, Sichuan 610041, China

Received: 7 September 2022 / Accepted: 3 July 2023

Published online: 05 July 2023

References

1. Navarro-Flores A, Fernandez-Chinguel JE, Pacheco-Barrios N, Soriano-Moreno DR, Pacheco-Barrios K. Global morbidity and mortality of central nervous system tuberculosis: a systematic review and meta-analysis. *J Neurol*. 2022;269(7):3482–94.
2. Modi M, Sharma K, Prabhakar S, Goyal MK, Takkar A, Sharma N, Garg A, Faisal S, Khandelwal N, Singh P, et al. Clinical and radiological predictors of outcome in tubercular meningitis: a prospective study of 209 patients. *Clin Neurol Neurosurg*. 2017;161:29–34.
3. Hsu PC, Yang CC, Ye JJ, Huang PY, Chiang PC, Lee MH. Prognostic factors of tuberculous meningitis in adults: a 6-year retrospective study at a tertiary hospital in northern Taiwan. *J Microbiol Immunol Infect*. 2010;43(2):111–8.
4. van Crevel R, Ruslami R, Aarnoutse R. Therapy for tuberculous meningitis. *N Engl J Med*. 2016;374(22):2187.
5. Chou CH, Lin GM, Ku CH, Chang FY. Comparison of the APACHE II, GCS and MRC scores in predicting outcomes in patients with tuberculous meningitis. *Int J Tuberculosis Lung Disease*. 2010;14(1):86–92.
6. Van TT, Farrar J. Tuberculous meningitis. *J Epidemiol Commun Health*. 2014;68(3):195–6.
7. Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in asian population. *Int archives Med*. 2012;5(1):1–6.
8. Zhou T, Zheng N, Li X, Zhu D, Han Y. Prognostic value of neutrophil-lymphocyte count ratio (NLCR) among adult ICU patients in comparison to APACHE II score and conventional inflammatory markers: a multi center retrospective cohort study. *BMC Emerg Med*. 2021;21(1):1–10.
9. Han Y, Kim SJ, Lee SH, Sim YS, Ryu YJ, Chang JH, Shim SS, Kim Y, Lee JH. High blood neutrophil-lymphocyte ratio associated with poor outcomes in miliary tuberculosis. *J Thorac disease*. 2018;10(1):339.
10. Widjaja H, Rusmawatiningsy D, Makrufardi F, Arguni E. Neutrophil lymphocyte ratio as predictor of mortality in pediatric patients with bacterial meningitis: a retrospective cohort study. *Annals of Medicine and Surgery*. 2022;73:103191.
11. Marais S, Thwaites G, Schoeman JF, Török ME, Misra UK, Prasad K, Donald PR, Wilkinson RJ, Marais BJ. Tuberculous meningitis: a uniform case definition for use in clinical research. *Lancet Infect Dis*. 2010;10(11):803–12.
12. Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. *BMC Med*. 2020;18(1):1–16.
13. Marchetti C, D'Indinosante M, Bottoni C, Di Ilio C, Di Berardino S, Costantini B, Minucci A, Vertechy L, Scambia G, Fagotti A. NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer. *Sci Rep*. 2021;11(1):1–8.
14. Ayers KL, Ma M, Debussche G, Corrigan D, McCafferty J, Lee K, Newman S, Zhou X, Hirsch FR, Mack PC. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. *BMC Cancer*. 2021;21(1):1–11.
15. Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. *Clin Chim Acta*. 2008;395(1–2):27–31.
16. Adamstein NH, MacFadyen JG, Rose LM, Glynn RJ, Dey AK, Libby P, Tabas IA, Mehta NN, Ridker PM. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. *Eur Heart J*. 2021;42(9):896–903.
17. Chedid C, Kokhraidze E, Tukvadze N, Banu S, Uddin MKM, Biswas S, Rusomando G, Acosta CCD, Arenas R, Ranaivomanana PP. Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study. *Int J Infect Dis*. 2020;100:199–206.
18. Okamura K, Nagata N, Wakamatsu K, Yonemoto K, Ikegame S, Kajiki A, Takayama K, Nakanishi Y. Hypoalbuminemia and lymphocytopenia are predictive risk factors for in-hospital mortality in patients with tuberculosis. *Intern Med*. 2013;52(4):439–44.
19. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Aboyans V, Adetokunboh O, Afshin A, Agrawal A. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of Disease Study 2016. *The Lancet*. 2017;390(10100):1151–210.
20. Srivastava S, Ernst JD, Desvignes L. Beyond macrophages: the diversity of mononuclear cells in tuberculosis. *Immunol Rev*. 2014;262(1):179–92.
21. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. *Bratisl Lek Listy*. 2001;102(1):5–14.
22. Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis infections. *Microbiol Spectr*. 2019;7(4):7.
23. Yin Y, Kuai S, Liu J, Zhang Y, Shan Z, Gu L, Huang Q, Pei H, Wang J. Pretreatment neutrophil-to-lymphocyte ratio in peripheral blood was associated with pulmonary tuberculosis retreatment. *Archives of Medical Science*. 2017;13(2):404–11.
24. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *JNCI: J Natl Cancer Inst* 2014, 106(6).
25. Abakay O, Abakay A, Sen HS, Tanrikulu AC. The relationship between inflammatory marker levels and pulmonary tuberculosis severity. *Inflammation*. 2015;38(2):691–6.
26. Cherian A, Thomas S. Central nervous system tuberculosis. *Afr Health Sci* 2011, 11(1).
27. Misra U, Kalita J, Roy A, Mandal S, Srivastava M. Role of clinical, radiological, and neurophysiological changes in predicting the outcome of tuberculous meningitis: a multivariable analysis. *J Neurol Neurosurg Psychiatry*. 2000;68(3):300–3.
28. Kalita J, Misra UK, Ranjan P. Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis. *Eur J Neurol*. 2007;14(1):33–7.
29. Pehlivanoglu F, Kart Yasar K, Sengoz G. Tuberculous meningitis in adults: a review of 160 cases. *The Scientific World Journal* 2012, 2012.
30. Li K, Tang H, Yang Y, Li Q, Zhou Y, Ren M, Long X, Shen W, Hu R, Wang X, et al. Clinical features, long-term clinical outcomes, and prognostic factors of tuberculous meningitis in West China: a multivariate analysis of 154 adults. *Expert Rev anti-infective therapy*. 2017;15(6):629–35.
31. Sharma P, Garg RK, Verma R, Singh MK, Shukla R. Incidence, predictors and prognostic value of cranial nerve involvement in patients with tuberculous meningitis: a retrospective evaluation. *Eur J Intern Med*. 2011;22(3):289–95.
32. Feng B, Fei X, Sun Y, Zhang X, Shang D, Zhou Y, Sheng M, Xu J, Zhang W, Ren W. Prognostic factors of adult tuberculous meningitis in intensive care unit: a single-center retrospective study in East China. *BMC Neurol*. 2021;21(1):1–11.
33. Sheu JJ, Hsu CY, Yuan RY, Yang CC. Clinical characteristics and treatment delay of cerebral infarction in tuberculous meningitis. *Intern Med J*. 2012;42(3):294–300.
34. Huang HJ, Ren ZZ, Dai YN, Tong YX, Yang DH, Chen MJ, Huang YC, Wang MS, Zhang JJ, Song WY, et al. Old age and hydrocephalus are associated with poor prognosis in patients with tuberculous meningitis: a retrospective study in a chinese adult population. *Medicine*. 2017;96(26):e7370.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.